Skip to main content
Equibles
TARS logo

TARS · Tarsus Pharmaceuticals, Inc. · Metrics

Track TARS — free

Use TARS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TARS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$70.76 +0.73 (+1.04%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$3.15B
Shares
43.88M
Volume · Oct 27 747.97K Avg daily vol (3M) 843.45K

TARS metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$70.76
Market cap
$3.15B

Price action

20 metrics
Price change (1W)
-0.4%
Price change (30D)
-7.9%
Price change (3M)
+20.0%
Price change (6M)
+14.0%
Price change (YTD)
-13.6%
Price change (1Y)
+3.8%
Trailing year
Price change (5Y)
+156.9%
52-week high
$90.78
52-week low
$56.11
Change from 52-week high
-22.1%
Change from 52-week low
+26.1%
Annualized volatility
44.9%
Annualized volatility (3M)
48.1%
Beta
0.7
RSI (14D)
46.1
Price vs SMA 50
-5.7%
Price vs SMA 200
+4.4%
Avg volume (3M)
843,446
Relative volume
0.9
Average dollar volume
$61.68M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
43.88M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.6×
reciprocal yield 21.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.2×
reciprocal yield 19.3%
P / book
9.1
reciprocal yield 11.0%
FCF yield
1.8%
TTM · current market cap
Buyback yield
—
P / FCF
56.2
reciprocal yield 1.8%
P / operating cash flow
42.4
reciprocal yield 2.4%
Earnings yield
-1.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.4×
reciprocal yield 9.6%
EV / revenue historical average (5Y)
9.8×
reciprocal yield 10.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-8.0%
Trailing 12 months
Net margin
-7.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$48.53M
Net income (TTM)
−$46.48M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
9.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$14.11
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.13
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.08
Operating cash flow per diluted share (TTM)
$1.72
Free cash flow per diluted share (TTM)
$1.29
Capital expenditures per diluted share (TTM)
$0.42
R&D per diluted share (TTM)
$2.04
Stock compensation per diluted share (TTM)
$1.21
Book value per share
$8.07

Growth

11 metrics
Revenue growth YoY
+69.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$606.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
+159.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-13.4%
Return on assets
-7.6%
Debt / equity
0.2
Current ratio
3.2
EBITDA (TTM)
—
Free cash flow (TTM)
$56.00M
Quick ratio
3.2
Interest coverage
-5.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$376.93M
Latest balance sheet
Cash & equivalents
$204.59M
Total assets
$611.14M
Total debt
$72.76M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$74.16M
Capital expenditures (TTM)
$18.16M
R&D (TTM)
$87.68M
SG&A (TTM)
$526.44M
Stock compensation (TTM)
$51.81M
R&D / revenue
14.5%
Stock compensation / revenue
8.5%

Ownership (13F)

9 metrics
13F filers
258
13F filer change QoQ
+4
Institutional ownership
110.0%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.2%
Holder tenure
11.1
Price vs estimated holder cost
+44.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.3%

Short interest

3 metrics
Short interest
13.1%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$5.19M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 33 filings 33 filers Visit website Investor relations